NEWRON PHARMACEUT. EO-,20/ IT0004147952 /
| 2024-11-15 11:00:52 PM | Chg. -0.280 | Volume | Bid11:00:52 PM | Ask11:00:52 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 7.760EUR | -3.48% | - Turnover: - |
7.760Bid Size: - | 7.900Ask Size: - | 138.75 mill.EUR | - | - |
Assets
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | .1000 | .1000 | .0900 | .0720 | .4050 | ||||||
| Intangible Assets | .0200 | .0100 | .0100 | 0.0000 | - | ||||||
| Long-Term Investments | 0.0000 | 0.0000 | 0.0000 | - | - | ||||||
| Fixed Assets | .3000 | 13.3000 | 11.1000 | 8.7020 | 6.2140 | ||||||
| Inventories | 0.0000 | 0.0000 | 0.0000 | - | - | ||||||
| Accounts Receivable | - | - | - | 5.7190 | 7.0530 | ||||||
| Cash and Cash Equivalents | 22.1000 | 13.2000 | 25 | 13.4240 | 6.3380 | ||||||
| Current Assets | 59.9000 | 37.9000 | 39.4000 | 28.4930 | 19.6520 | ||||||
| Total Assets | 60.3000 | 51.2000 | 50.5000 | 37.1950 | 25.8660 | ||||||
Liabilities
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 5.5000 | 6.7000 | 3.5000 | 4.8690 | 6.1060 | ||||||
| Long-term debt | 16.7000 | 25.7000 | 42.5000 | 65.4900 | 25.7530 | ||||||
| Liabilities to Banks | 16.7000 | 25.7000 | 42.5000 | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 23.5000 | 34 | 47.4000 | 51.2250 | 55.7740 | ||||||
| Share Capital | 3.6000 | 3.6000 | 3.6000 | - | - | ||||||
| Total Equity | 36.8000 | 17.2000 | 3.1000 | -14.0300 | -29.9080 | ||||||
| Minority Interests | - | - | - | - | 0.0000 | ||||||
| Total liabilities equity | 60.3000 | 51.2000 | 50.5000 | 37.1950 | 25.8660 | ||||||
Income Statement
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 7 | 5.3000 | 5.8000 | 6.0940 | 9.0570 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -20.9000 | -18.1000 | -12.4000 | -13.3020 | -11.6290 | ||||||
| Interest Income | - | - | - | -4.1700 | -4.5710 | ||||||
| Income Before Taxes | -20.2000 | -19.6000 | -14.9000 | - | - | ||||||
| Income Taxes | 0.0000 | -1.4000 | 0.0000 | .0210 | .0240 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Net Income | -20.2000 | -21 | -14.9000 | -17.4930 | -16.2240 | ||||||
Per Share
Cash Flow
|
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
2021 IFRS in mill. EUR |
2022 IFRS in mill. EUR |
2023 IFRS in mill. EUR |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -22.2000 | -15.6000 | -11.4000 | -11.0920 | -10.1400 | ||||||
| Cash Flow from Investing Activities | -.9000 | -.6000 | 8.4000 | -.3170 | 3.2460 | ||||||
| Cash Flow from Financing | 17.6000 | 7.4000 | 14.8000 | -.1860 | -.1920 | ||||||
| Decrease / Increase in Cash | -5.6000 | -8.8000 | 11.8000 | - | - | ||||||
| Employees | 26 | 23 | 25 | - | - | ||||||
